Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (Diluted Average) (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $89.9 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 911.73% to $89.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $89.9 million through Sep 2025, up 911.73% year-over-year, with the annual reading at $23.7 million for FY2024, 293.35% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $89.9 million at Inhibikase Therapeutics, roughly flat from $89.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $89.9 million in Q3 2025, with the low at $4.2 million in Q4 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $23.5 million, with a median of $8.2 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) plummeted 77.85% in 2023, then skyrocketed 1312.1% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $18.2 million in 2021, then tumbled by 76.81% to $4.2 million in 2022, then soared by 42.74% to $6.0 million in 2023, then skyrocketed by 293.35% to $23.7 million in 2024, then skyrocketed by 278.99% to $89.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $89.9 million, $89.8 million, and $89.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.